Answers are grounded in this paper and cite their sources.
Inhibition of cathepsin B improves survival in cardiomyocytes during reperfusion injury, suggesting new therapeutic approaches.
Background Inflammation plays a pivotal role in modulating the pathophysiological progression of myocardial injury and the subsequent repair and remodeling of the infarcted myocardium. Cathepsin B, a member of the cysteine protease family, has been recognized for its ability to initiate various signaling cascades essential to inflammatory processes. This study aims to investigate whether cathepsin B influences cardiomyocyte survival under inflammatory conditions. Methods Mice were randomly divided into four groups ( n = 6 per group) based on whether they received an intraperitoneal injection of Ca-074 Me (50 mg/kg) and whether myocardial ischemia/reperfusion (I/R) surgery was performed. Results The cathepsin B-specific inhibitor Ca-074 Me significantly attenuated myocardial infarction caused by I/R in vivo and reduced hypoxia-induced cardiomyocyte apoptosis in vitro . Mechanistically, Ca-074 Me appeared to inhibit caspase-3 signaling, thereby mitigating cardiomyocyte apoptosis under chemical hypoxia induced by cobalt chloride or physical oxygen deprivation. Conclusion Targeted inhibition of cathepsin B may represent an innovative strategy for the amelioration of myocardial injury.
No takes yet. Share an insight, caveat, or question.
Su et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: